1279088-80-0 Usage
Uses
Used in Pharmaceutical Research:
1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a research compound for the development of new pharmaceutical agents. Its unique structure and reactivity make it a promising candidate for the design of novel drugs with potential therapeutic applications.
Used in Materials Science:
In the field of materials science, 1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a component in the synthesis of new materials with specific properties. Its ability to form stable complexes and its reactivity with other molecules can contribute to the creation of advanced materials with applications in various industries.
Used in Organic Synthesis:
1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a building block in organic synthesis for the creation of more complex organic molecules. Its unique structure allows for a wide range of chemical reactions, making it a valuable tool for chemists in designing and synthesizing new organic compounds with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1279088-80-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,7,9,0,8 and 8 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1279088-80:
(9*1)+(8*2)+(7*7)+(6*9)+(5*0)+(4*8)+(3*8)+(2*8)+(1*0)=200
200 % 10 = 0
So 1279088-80-0 is a valid CAS Registry Number.
1279088-80-0Relevant academic research and scientific papers
Triazine tripyrazole compound as well as preparation method and application thereof
-
Paragraph 0012; 0034-0038, (2020/06/09)
The invention provides a triazine tripyrazole compound as well as a preparation method and application thereof. The structural formula of the triazine tripyrazole compound is shown as a formula (I). Preferably, the name of the triazine tripyrazole compoun
SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE
-
, (2017/08/01)
The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.
